Clifford Swan Investment Counsel LLC Cuts Stock Holdings in Pfizer Inc. $PFE

Clifford Swan Investment Counsel LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 11.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 502,714 shares of the biopharmaceutical company’s stock after selling 66,458 shares during the quarter. Clifford Swan Investment Counsel LLC’s holdings in Pfizer were worth $12,809,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in PFE. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Pfizer in the third quarter worth about $29,000. Howard Hughes Medical Institute bought a new stake in Pfizer in the 2nd quarter worth approximately $30,000. Darwin Wealth Management LLC purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $32,000. Evelyn Partners Asset Management Ltd bought a new position in shares of Pfizer during the 2nd quarter valued at approximately $33,000. Finally, True Wealth Design LLC grew its holdings in shares of Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.1%

Shares of NYSE:PFE opened at $27.11 on Friday. The firm has a market capitalization of $154.14 billion, a PE ratio of 19.93 and a beta of 0.47. The business has a 50 day simple moving average of $26.08 and a two-hundred day simple moving average of $25.39. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.94. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same quarter last year, the firm posted $0.63 earnings per share. The business’s revenue was down 1.2% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. Pfizer’s dividend payout ratio (DPR) is presently 126.47%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Morgan Stanley decreased their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Barclays initiated coverage on shares of Pfizer in a report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target for the company. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Finally, Wolfe Research set a $24.00 price objective on Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average price target of $27.70.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA grants full approval to Pfizer’s BRAFTOVI regimen for metastatic colorectal cancer — expands label to first‑line use, supporting upside to oncology sales and the “bull case” narratives for PFE. Pfizer’s Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment
• Positive Sentiment: Analyses argue the BRAFTOVI approval could re‑shape Pfizer’s growth outlook in oncology, providing a clear revenue catalyst if uptake in first‑line mCRC is strong. The Bull Case For Pfizer (PFE) Could Change Following New First-Line BRAFTOVI Colorectal Cancer Approval
• Positive Sentiment: Pfizer secures rights to a new GLP‑1 candidate as the company broadens its obesity pipeline — a strategic move to chase a large market and diversify future revenue streams. Pfizer secures rights to new GLP-1 as obesity push gathers pace
• Neutral Sentiment: Dividend narrative remains supportive: articles highlighting Pfizer’s 6%+ yield and retiree flows into dividend funds underscore investor appetite for PFE income, which can stabilize the stock. Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.
• Neutral Sentiment: Zacks upgraded Pfizer from “strong sell” to “hold,” a modest positive signal but not a bullish re‑rating; it may temper short‑term selling. Zacks.com
• Negative Sentiment: RBC Capital initiated coverage with an Underperform and $25 target, warning of an “insurmountable” $15B–$20B revenue decline through 2030 — a bearish structural thesis that could cap valuation upside. RBC Capital Initiates Pfizer (PFE) with $25 Target, Warns of Structural Revenue Headwinds
• Negative Sentiment: Pfizer terminated an early‑stage ulcerative colitis study — a pipeline setback that reduces optionality in immunology and may modestly pressure sentiment. Pfizer Terminates Early-Stage Ulcerative Colitis Drug Study

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.